Search results
Results From The WOW.Com Content Network
The three established speciality journals (The Lancet Neurology, The Lancet Oncology, and The Lancet Infectious Diseases) have built up strong reputations in their medical speciality. According to the Journal Citation Reports , The Lancet Oncology has a 2021 impact factor of 54.433, The Lancet Neurology has 59.935, and The Lancet Infectious ...
In 1998, the number of manuscripts submitted had risen from 500 in the first year to almost 800. The journal reported an acceptance rate of 52% at that time. With the aim to publish only papers of high quality, the editors decided to increase the stringency of review. [3]
The acceptance rate is less than 7% for original research articles. [18] At the beginning of February 2021, The BMJ introduced a charge of £299 for publishing obituaries. This was widely criticized on social media, by the British Medical Association among others, because of the large number of medical staff being killed by COVID-19. [19]
The journal's logo depicts the snake-wrapped Rod of Asclepius crossed over a quill pen. The dates on the logo represent the founding of the components of The New England Journal of Medicine: 1812 for the New England Journal of Medicine and Surgery and Collateral Branches of Medical Science, 1823 for the Boston Medical Intelligencer, 1828 for the Boston Medical and Surgical Journal, and 1928 ...
The Lancet#Specialty journals To a section : This is a redirect from a topic that does not have its own page to a section of a page on the subject. For redirects to embedded anchors on a page, use {{ R to anchor }} instead .
After all, the death rate for cancer has continued to drop from 2016 to today, ... another study in The Lancet reported that nearly three-quarters of U.S. adults are overweight or obese. As one ...
In 2023 the American Society of Clinical Oncology announced a new pill that cut the risks of a patient dying from lung cancer by over 50%. The comprehensive study was conducted with patients between the ages of 30 and 86 in 26 different countries.
The mean response rate for new cancer drugs approved by the U.S. Food and Drug Administration, expressed as relative risk, ranges between 1.38x [3] and 2.37x. [ 4 ] See also